Yarrow Bioscience R&D Spending Growth & History (YARW)
Yarrow Bioscience's r&d spending was $19.2M for fiscal 2025.
View full Yarrow Bioscience company overviewYarrow Bioscience annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $19.2M | −$11.7M | −37.84% |
| 2024 | 2024-12-31 | $30.9M | $14.6M | +89.77% |
| 2023 | 2023-12-31 | $16.3M | −$2.1M | −11.30% |
| 2022 | 2022-12-31 | $18.4M | −$1.2M | −5.93% |
| 2021 | 2021-12-31 | $19.5M | −$24.0M | −55.11% |
| 2020 | 2020-12-31 | $43.5M | −$7.7M | −14.98% |
| 2019 | 2019-12-31 | $51.2M | −$13.3M | −20.59% |
| 2018 | 2018-12-31 | $64.5M | $35.5M | +122.27% |
| 2017 | 2017-12-31 | $29.0M | $17.8M | +157.73% |
| 2016 | 2016-12-31 | $11.3M | $8.3M | +285.31% |
| 2015 | 2015-12-31 | $2.9M | — | — |
Yarrow Bioscience quarterly r&d spending
| Fiscal quarter | Period ended | R&D spending | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $788,000 | −$4.1M | −83.86% |
| Q1 2026 | 2026-03-31 | $817,000 | −$5.3M | −86.66% |
| Q4 2025 | 2025-12-31 | $604,000 | −$9.1M | −93.76% |
| Q2 2025 | 2025-06-30 | $4.9M | −$2.4M | −33.19% |
| Q1 2025 | 2025-03-31 | $6.1M | $2.4M | +65.16% |
| Q4 2024 | 2024-12-31 | $9.7M | $6.7M | +220.45% |
| Q3 2024 | 2024-09-30 | $10.2M | $6.9M | +208.86% |
| Q2 2024 | 2024-06-30 | $7.3M | $73,000 | +1.01% |
| Q1 2024 | 2024-03-31 | $3.7M | $974,000 | +35.63% |
| Q4 2023 | 2023-12-31 | $3.0M | −$1.3M | −29.38% |
| Q3 2023 | 2023-09-30 | $3.3M | −$2.2M | −40.17% |
| Q2 2023 | 2023-06-30 | $7.2M | $3.1M | +76.07% |
| Q1 2023 | 2023-03-31 | $2.7M | −$1.7M | −38.59% |
| Q4 2022 | 2022-12-31 | $4.3M | −$44,000 | −1.02% |
| Q3 2022 | 2022-09-30 | $5.5M | −$371,000 | −6.27% |
| Q2 2022 | 2022-06-30 | $4.1M | −$940,000 | −18.62% |
| Q1 2022 | 2022-03-31 | $4.5M | $197,000 | +4.63% |
| Q4 2021 | 2021-12-31 | $4.3M | −$3.5M | −44.85% |
| Q3 2021 | 2021-09-30 | $5.9M | −$706,000 | −10.66% |
| Q2 2021 | 2021-06-30 | $5.0M | −$8.1M | −61.52% |
| Q1 2021 | 2021-03-31 | $4.3M | −$11.7M | −73.33% |
| Q4 2020 | 2020-12-31 | $7.8M | −$7.5M | −48.92% |
| Q3 2020 | 2020-09-30 | $6.6M | −$5.8M | −46.81% |
| Q2 2020 | 2020-06-30 | $13.1M | $563,000 | +4.48% |
| Q1 2020 | 2020-03-31 | $16.0M | $5.1M | +47.06% |
| Q4 2019 | 2019-12-31 | $15.3M | −$11.2M | −42.22% |
| Q3 2019 | 2019-09-30 | $12.5M | $1.8M | +16.73% |
| Q2 2019 | 2019-06-30 | $12.6M | −$3.7M | −22.62% |
| Q1 2019 | 2019-03-31 | $10.8M | −$172,000 | −1.56% |
| Q4 2018 | 2018-12-31 | $26.6M | $16.0M | +151.83% |
| Q3 2018 | 2018-09-30 | $10.7M | $2.7M | +33.20% |
| Q2 2018 | 2018-06-30 | $16.2M | $10.8M | +197.18% |
| Q1 2018 | 2018-03-31 | $11.0M | $6.0M | +120.75% |
| Q4 2017 | 2017-12-31 | $10.5M | — | — |
| Q3 2017 | 2017-09-30 | $8.0M | — | — |
| Q2 2017 | 2017-06-30 | $5.5M | — | — |
| Q1 2017 | 2017-03-31 | $5.0M | — | — |
Yarrow Bioscience r&d spending trends
Over the last five fiscal years, Yarrow Bioscience's r&d spending decreased from $43.5M to $19.2M, a change of −$24.3M. The latest reported quarter, Q2 2026, shows $788,000.
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Yarrow Bioscience source filings ↗